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Summary Immunocytochemistry with monoclonal antibody Y13-259 demonstrated p21 ras in paraffin sec-
tions of breast tissue from 171 women: 85 with invasive breast carcinoma, 14 with non-invasive carcinoma and
72 with benign changes only. Many different tissue elements contributed to ras expression. Semiquantitative
assessment showed that intensity of immunostaining in the normal epithelium of large ducts, small extra-
lobular ducts and terminal duct lobular units (TDLU) was usually exceeded by that of myoepithelial cells.
Vascular smooth muscle and apocrine epithelium also stained strongly, but the flat epithelial cells lining cysts
did not express detectable p21 ras. There was a progressive increase from normal epithelium through epithelial
hyperplasia of usual type and atypical hyperplasia to carcinoma in situ, without further increase in invasive
carcinoma. Expression in carcinomas was inversely related to oestrogen receptor content but independent of
the prognosis-associated variables of size, histological type, vascular invasion or lymph node metastasis.
The role of ras genes in human mammary carcinogenesis
remains undefined. Ras mutations are rare in breast car-
cinomas (Rochlitz et al., 1989) and gene amplification has
not been recorded, but there are conflicting observations
(reviewed by Field & Spandidos, 1990) of ras protein expres-
sion. Hyperexpression has often been recorded (Spandidos &
Agnantis, 1984; Ohuchi et al., 1986; De Bortoli et al., 1985;
Clair et al., 1987; Fromowitz et al., 1987), but some immuno-
cytochemical studies with the antibodies RAP-5 (Ghosh et
al., 1986) and Y13-259 (Candlish et al., 1986; Walker &
Wilkinson, 1988) have found no increased reactivity in car-
cinomas compared with benign parenchyma. Walker and
Wilkinson (1988) suggested that expression in carcinomas
was actually less than in normal parenchyma. Some of the
discrepancies may reflect methodological differences. Conclu-
sions from immunocytochemical data, for example, have
been clouded by the now proven nonspecificity of RAP-5
(Robinson et al., 1986; Rochlitz et al., 1988; Samowitz et al.,
1988; Gutheil et al., 1989). Interpretation of biochemical
measurements of ras mRNA or protein is confounded by
inclusion of many different cell types in the tissue homo-
genates analysed.
In this study we have used the pan-ras antibody Y13-259
(Furth et al., 1982). It is a well characterised rat monoclonal
IgGj, (Lacal et al., 1986), and when bound to its epitope,
blocks the interaction of p21 ras with its potential down-
stream effector molecule, GTPase activating protein (GAP)
(Srivastava et al., 1989). This epitope does not survive con-
ventional aldehyde fixation well, but cryostat sections fixed in
acetone (which conserves the epitope) are unsuitable for
critical assessment of breast histology. Excellent preservation
of morphology and Y13-259 immunoreactivity are obtained,
however, in paraffin-embedded tissue fixed in periodate-
lysine-paraformaldehyde (PLP) and its dichromate derivative
(PLPD) (Going et al., 1988a). These fixatives preserve mem-
brane localisation of p21 ras in transformed rodent fibro-
blasts expressing mutant p21 ras. No studies of human
carcinoma have so far demonstrated the expected localisation
of p21 ras to the plasma membrane (Going et al., 1988a;
Williams et al., 1985; Chesa et al., 1987; Walker & Wilkin-
son, 1988). We therefore examined the cellular location of
p21 ras in normal, hyperplastic and neoplastic breast tissue
from 171 women, and used a semiquantitative scoring system
to compare its staining intensity in immunocytochemical
preparations that clearly display the different cell types and
pathological states.
Materials and methods
Patients and tissue selection
One hundred and seventy-one women treated at the Breast
Unit, Longmore Hospital, Edinburgh, formed the study
population. Those who had received prior chemotherapy,
radiotherapy, or endocrine manipulation by surgery or drugs
were excluded. Three-mm slices were prepared from biopsy
and mastectomy specimens collected immediately onto ice.
Blocks were selected by naked-eye or dissecting-microscope
inspection before or after supravital staining with methylene
blue in ice-cold nutrient medium (Buehring & Jensen, 1983)
to identify areas of abnormal parenchyma.
Fixation andprocessing
Tissues were fixed in periodate-lysine-paraformaldehyde-dich-
romate (PLPD), processed to paraffin, and 4tm sections
immunostained with monoclonal antibody Y13-259 (obtain-
able from Oncogene Science) and an avidin-biotin detection
system (Dako), together with appropriate controls (Going et
al., 1988a). Morphological assessment of haematoxylin and
eosin sections, including the diagnosis of special types of
carcinoma, was by published criteria (Page & Anderson,
1987) and included comparison with diagnostic material fixed
in buffered formaldehyde.
Scoring
Intensity of immunostaining was scored 0-3 (negative-strong
positive). Extent of immunostaining within a cellular popula-
tion was scored 1-4 (0-25% positive = 1; 25-50% = 2;
50-75% = 3; 75-100% = 4). Intensity scores of 2 and 3
were added to the extent score to give a single composite
score. In forming this composite score equivocally positive
staining (intensity scoring 1) was ignored (Table I) to avoid
giving undue weight to populations in which positivity was
doubtful. For each section, composite scores were obtained
separately for individual cell types (e.g. epithelium, myo-
epithelium, stromal fibroblasts) and, as appropriate, for each
diagnostic category (e.g. normal, typical hyperplasia, atypical
hyperplasia, carcinoma in situ etc).
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Table I Combination of extent and intensity scores for p21 ras
immunocytochemistry to give an overall score (0-7)
Extent score
1 2 3 4
Intensity 0 - - - 0
Score 1 1 1 2 2
2 3 4 5 6
3 4 5 6 7
0 implies no staining at all, seven implies strong immunostaining of
75 1 I00% of the cells in a defined population.
Statistical analysis
Scoring was validated in 42 randomly chosen cases by rep-
etition without knowledge of previously assigned scores,
yielding 311 pairs of scores for separate populations of
parenchymal and stromal cells. Acceptable repeatability of
scoring was obtained (Spearman's rank correlation
coefficient= 0.75, P<0.001). There was no systematic bias
between scoring runs, assessed by Wilcoxon's matched-pairs
signed ranks test (P>0.05). Comparison of composite im-
munostaining scores was performed by the two-tailed two-
sample Kolmogorov-Smirnov test. This non-parametric test
uses the greatest difference between cumulative frequency
distributions of the samples under comparison (Sokal &
Rohlf, 1981). Accordingly, the semiquantitative analyses in
this paper are displayed as cumulative frequency curves
rather than the more familiar frequency distribution histo-
grams. Such plots show, in the form of a continuous curve,
the percentage of cases in the studied population with scores
that fall on or below the values displayed on the horizontal
axis. The highest score recorded in a population is indicated
by the value at which the curve reaches 100%, and the
median score by the 50% point. Thus, generally low-scoring
populations are represented by curves situated to the left of
the plot, reaching 50% and 100% at relatively low score
values. Populations with high scores appear as curves shifted
to the right. The Kolmogorov-Smirnov test measures the
significance of this shift.
Oestrogen receptor status
Oestrogen receptors were measured as previously described
(Hawkins et al., 1981) in homogenates made from tissue
taken adjacent to the site selected for histology.
Results
Normal breast
p21 ras expression in normal epithelium was weak and
heterogenous. On semiquantitative assessment there was no
difference in expression between ductules of terminal duct
lobular units (TDLU), small extra-lobular ducts and larger
ducts, and as both ductal and lobular carcinomas are
thought to arise from TDLU (Wellings & Jensen, 1973), the
epithelium of TDLU was selected to represent normal paren-
chyma in subsequent comparisons. Expression was the same
in morphologically normal TDLU of women with cancer and
women with benign changes only, but TDLU of women
younger than 45 (the median age in our study population)
expressed p21 ras more strongly than those of women aged
45 or over (P<0.01).
Myoepithelial cells in common with epithelial cells showed
no difference in expression between large ducts, small ducts
and TDLU, but overall expression in myoepithelial cells was
consistently stronger than in epithelial cells (P<0.001; Fig-
ure la). Immunoreactivity with Y13-259 was also strong in
vascular smooth muscle, and occasionally in normal endo-
thelial cells (Figure lb).
Epithelium lining cysts
Apocrine cyst epithelium was usually positive for p21 ras
immunostaining, but some different patterns of ras expres-
sion were seen. In most cases there was distinct membrane
localisation, usually apical, but in some cases baso-lateral
(Figure Ic). In contrast the flattened simple epithelium
of many cysts was consistently negative for p21 ras
(P<0.0001).
Hyperplastic and atypical epithelium
There was progressively stronger and more extensive p21 ras
expression from normal through hyperplastic and atypical
epithelium to non-invasive carcinoma. Figure 2 presents p21
ras score data for usual and atypical ductal hyperplasias as
well as normal TDLU, ductal carcinoma in situ (DCIS) and
invasive carcinomas. The P values of differences between
populations are listed in the caption. A similar progressive
increase was seen from normal lobules through atypical
lobular hyperplasia to lobular carcinoma in situ, but the
numbers were too small for useful separate statistical analy-
SiS.
Carcinomas
Immunostaining for p21 ras was consistently strong in car-
cinomas. There was no difference in extent and intensity of
immunostaining between non-invasive and invasive carcin-
oma, whether ductal or lobular. Expression of p21 ras was
almost invariably stronger in carcinomas than in benign
epithelium from the same patient. Some heterogeneity of
expression was seen, with weakly staining or negative car-
cinoma cells adjacent to strongly expressing cells, but in
many cases, uniform strong expression was observed in
almost all malignant cells. One carcinoma only was devoid of
detectable p21 ras while adjacent benign parenchyma was
positive. Stromal cells of carcinomas were also consistently
positive for p21 ras. Although not as strongly positive as
carcinoma cells (P<0.001), they stained much more strongly
than stromal cells of normal TDLU (P<0.0001).
In many carcinomas in which p21 ras was strongly ex-
pressed, cells undergoing apoptosis and cells in areas of
confluent necrosis lost Y13-259 immunoreactivity (Figure
Id). This was also true for cells retaining some nuclear
chromatin at the edge of areas of confluent necrosis, and
there was usually a sharp transition from expression to non-
expression.
Cellular location ofp21 ras
In almost all carcinomas, invasive or non-invasive, p21 ras
expression was intracytoplasmic (Figure Id). A few cases
showed membrane as well as cytoplasmic positivity, and one
lobular invasive carcinoma was unique in this human mater-
ial in showing dominant membrane localisation (Figure le).
By contrast, there was almost exclusive membrane expression
in cells of a rodent fibroblast tumour expressing human
Ha-ras (Going et al., 1988a; Figure 1 f). In this tumour
membrane localisation persisted even when fixation was de-
liberately delayed by up to 30min (data not shown).
Factors in clinicopathological correlation
Carcinoma size and histology There were 18 invasive car-
cinomas of special histological type, including ten lobular,
two medullary, two mucoid, three cribriform invasive and
one tubular carcinoma. Sixty-seven were of no special type.
No association was observed between histology and p21 ras
expression. In particular, there was no correlation of p21
expression with types known to be associated with either
poor or good prognosis. Similarly there was no correlation of
p21 ras immunostaining with carcinoma diameter.
Lymph node status Accurate information from ipsilateral
axillary clearance or four-node sampling at the time ofP21 ras IN BREAST TISSUE 47
primary surgery was available for 66 carcinomas. Of these,
39 were node-negative, while 27 had one or more nodes
involved by carcinoma. There was no difference of p21 ras
expression between these groups, nor between the 14 node-
positive cases with one or two positive nodes and 13 cases
with three or more.
a
c
Vascular invasion Fifty-six carcinomas had no evidence of
vascular invasion in any sections, while in 29 vascular
invasion was observed. There was no difference of p21 ras
expression between these groups, but for the 20 cases in
which immunostained blocks of invasive carcinoma included




Figure 1 Immunocytochemistry for p21 ras with Y13-259, 50pgml-', ABC detection. a, Elongated myoepithelial cells with
cytoplasmic positivity. b, Cytoplasmic positivity in endothelium and vascular smooth muscle. c, Apocrine cyst epithelium:
Basolateral positivity. d, Cytoplasmic positivity in invasive carcinoma cells. Apoptotic carcinoma cells are negative. e, Membrane
expression of p21 ras by lobular invasive carcinoma. f, Membrane expression of human p21 Ha-ras by rodent fibrosarcoma
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Figure 2 Cumulative frequency curves of composite scores for
Y13-259 ABC immunostaining. a, Epithelium of normal TDLU
(156 cases). b, Ductal hyperplasia without atypia (72 cases). c,
Atypical ductal hyperplasia (33 cases). d, Ductal carcinoma in situ
(63 cases). e, Invasive carcinoma (all types: 86 cases). Differences
are significant as follows: a/b, P<0.05, a/c, P<0.001, a/d,
P<0.001, a/e, P<0.001; b/c, not significant, b/d, P<0.001, b/e,
P<0.001, c/d, P<0.05, c/e, P<0.05, d/e, not significant.
pare p21 ras expression in carcinoma cells within vascular
lumina and those present in adjacent stroma. Carcinoma cells
within vascular lumina expressed p21 ras less strongly than
the cells invading the stroma (P<0.05).
Oestrogen receptor status Table II illustrates the relation
between p21 ras immunostaining score and oestrogen recep-
tor expression. There were few oestrogen-receptor-negative
carcinomas with low scores (four or less) for p21 ras im-
munostaining. Taking 20 fmol mg-' of protein as a conven-
tional cut-off between receptor-positive and receptor-negative
carcinomas, only one (7%) of 15 carcinomas with low p21
ras score was receptor negative whereas of the 70 carcinomas
with high scores, 31 (44%) were receptor-negative (x2= 5.93,
P<0.025 including Yates' correction).
Discussion
Semi-quantitative immunocytochemistry ofp21 ras
Our semi-quantitative immunocytochemical method has de-
monstrated complex patterns of ras expression in human
breast that would be difficult to observe by other means,
including purely qualitative immunocytochemistry and
biochemical analysis of tissue homogenates. We have shown
that ras proteins are expressed by several cell types in non-
neoplastic breast, including myoepithelium and vascular
smooth muscle; that this expression often appears to exceed
that of the epithelial elements; and that - in carcinomas - ras
expression in stroma as well as epithelium may vary from
tumour to tumour. All of these observations demonstrate the
potential misconceptions that could arise from analysis of
breast tissue homogenates by purely biochemical means. One
immediately available example ofthis may be the relationship
between p21 ras and oestrogen receptor expression. In our
series of 85 carcinomas we show a significant inverse relation-
ship between oestrogen receptor expression and expression of
p21 ras. This was not observed in 54 previously reported
carcinomas studied as tissue homogenates (Clair et al., 1987),
although the overall incidence of oestrogen receptor
positivity in the two series is identical, the assays being
performed in the same laboratory. It is clearly impossible to
rank carcinomas in order of their epithelial p21 ras expres-
Table II Contingency table relating expression of p21 ras and
oestrogen receptor content [OR] of 85 carcinomas
p21 score p21 score
less thanfive five or more
[OR] >20fmolmg-' 14 39
[OR] <20 fmolmg-' 1 31
X2 = 5.93; P<0.025 (with Yates' correction).
sion on the basis of information from homogenates alone.
The central issues raised by the data presented here, how-
ever, relate to the predominant cytoplasmic location of ras
p21 and the function of this protein in breast hyperplasias
and carcinomas.
Cellular location ofp21 ras
In these studies p21 ras was found predominantly in the
cytoplasm. It is noteworthy that similar cytoplasmic location
has also been observed in several previous studies of p21,
using a variety of antibodies, in non-neoplastic human or
rodent tissues and some human tumours (Williams et al.,
1985; Bizub et al., 1987; Chesa et al., 1987; Furth et al., 1987;
Ward et al., 1989; Going et al., 1988a; Papadimitriou et al.,
1988; Tiniakos et al., 1989; Koutselini et al., 1990). Indeed,
distinctive membrane localisation is exceptional in human
and normal rodent tissues. The classical perception that the
majority of p21 molecules are anchored to the plasma mem-
brane derives - we believe exclusively - from studies of
transformed cells, usually rodent fibroblasts (Willingham et
al., 1980; Willumsen et al., 1984; Hancock et al., 1989).
Several explanations can be offered for this apparent dis-
crepancy.
First, it is possible that the observed cytoplasmic location
is artefactual, resulting from changes effected during fixation.
Although this trivial interpretation is commonly proposed, it
is clearly erroneous. PLPD, the fixative used here, was
developed because of its effectiveness in stabilising mem-
brane-linked epitopes (Holgate et al., 1986). In our hands
p21 ras was not displaced from the membrane of trans-
formed rodent fibroblasts by delayed fixation, and the memb-
rane localisation which was observed in the human breast
was restricted to specific minority cell types (for example
apocrine epithelium).
A second trivial explanation is that Y13-259 detects cyto-
plasmic epitopes other than p21 ras. Obvious candidates
would be other members of the expanding ras gene super-
family which share many common amino acid sequences with
ras proteins, but may lack plasma membrane localisation
(Bourne et al., 1991). The specificity and selectivity of Y13-
259 for p21 ras has been repeatedly demonstrated however,
in both immunoblotting and immunocytochemical contexts
(Furth et al., 1982; Robinson et al., 1986; Ward et al., 1989).
It detects Ha- Ki- and N-ras p21s, which have identical
amino acid sequence in and around the six critical positions
that define the antibody binding site. Single substitutions
involving any of these amino acids are known to diminish
antibody binding more than 1,000-fold (Sigal et al., 1986),
and such substitutions occur in all other members of the
superfamily (Chardin & Tavitian, 1986; Lowe et al., 1987;
Didsbury et al., 1989; Pizon et al., 1989; Nimmo et al., 1991).
A third possibility is that biologically effective p21 ras is
indeed restricted to the plasma membrane of breast epi-
thelium, but is present in relatively small amounts, the larger
quantities detected in cytoplasm representing either inactive
precursors or degradation products. Ras proteins are initially
synthesised as 23,000 kd molecules (called p23), that undergo
processing in the cytoplasm before anchorage to the plasma
membrane (Evans et al., 1991). In transformed fibroblasts,
p23 is short-lived and the majority species is membrane-
linked, processed p21 ras. Equivalent data are lacking for
normal epithelia, but in immunoblots of extracts prepared
from some of the breast biopsies studied here, Y13-259
invariably identified a protein doublet. It has not yet beenP21 ras IN BREAST TISSUE 49
established whether this is due to p23, a degradation product
with electrophoretic migration close to p21, or some other
modification (D. Watson & W.R. Miller, unpublished
results).
Finally, it remains possible that p21 ras need not be
anchored to the plasma membrane in order to be active.
Neither the GTPase activity of p21, nor p21 binding to
GTPase activating proteins (GAPs) is determined by the
C-terminus that mediates membrane association. GAPs are
vital in the physiological regulation of ras (Downward et al.,
1990) and may serve as downstream effectors (Bourne et al.,
1990). Moreover, of the two widely present cellular proteins
with ras-specific GAP activity, one (the neurofibromatosis-
linked protein, NF-1) does not show membrane localisation
and may mediate different effects of p21 ras from the
membrane-associated GAP (Bollag & McCormick, 1991).
Histological methods alone are incapable of distinguishing
these last two possibilities, but the unequivocally cytoplasmic
location of p21 ras expressed in breast tissue cells stimulates
enquiry into the role of this important molecule at this site.
p21 ras in breastpathology
It is tempting to assume that the p21 ras expression observed
here is in some way related to cell division. Circumstantial
evidence in support of this view includes the stepwise increase
in expression with increasing histological deviation from nor-
mality as documented here, the highest levels being fund in
carcinomas. The age-related decline in p21 expression of
normal TDLU epithelium also parallels a decline in prolifera-
tion rate (Going et al., 1988b). It is of course very well
established that ras proteins mediate cell proliferation in a
variety of other cell types (Feramisco et al., 1984; Mulcahy et
al., 1985; Downward et al., 1990). Nevertheless, p21 expres-
sion is also a feature of non-proliferating cells, such as the
myoepithelium described here (Joshi et al., 1986) and many
other cell types (Spandidos & Dimitrov 1985; Chesa et al.,
1987). Ras proteins mediate cellular processes as diverse as
neuronal differentiation (Bar-Sagi & Feramisco, 1985), mast
cell degranulation (Bar-Sagi & Gomperts, 1988), oocyte
maturation (Birchmeier et al., 1985) and cell cycle arrest
(Franza et al., 1986). It is therefore premature to conclude
that the sole or even major role of the ras expression which
we have observed in breast epithelial cells is to promote their
proliferation.
Despite uncertainty over its precise role in the breast, there
is much evidence to associate p21 ras expression and growth
control in the TDLU of both human and animal tissues
(Benz et al., 1989; Strange et al., 1989; Ciardiello et al., 1990;
Telang et al., 1990). This paper emphasises the graded altera-
tions in ras expression in the TDLU epithelium in hyper-
plasias and carcinoma in situ, and the absence of further
change in infiltrative and metastatic lesions. Somewhat simi-
lar observations have been made in human colorectal mucosa
in the adenoma-carcinoma sequence: both p21 ras expression
(Williams et al., 1985; Gallick et al., 1985) and the incidence
of Ki-ras mutation (Vogelstein et al., 1988) are predomi-
nantly features of adenomas, with no further increase in
carcinomas. A dominant common pathway of progression to
invasive cancer is less well characterised in the breast (Ander-
son, 1991) but it may be that here also, a major role of ras
expression is to alter epithelial cells in such a way that
further genetic changes, associated directly with carcino-
genesis, become more probable or more effective.
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